Docking Characterization and in vitro Inhibitory Activity of Flavan-3-ols and Dimeric Proanthocyanidins Against the Main Protease Activity of SARS-Cov-2

Yue Zhu and De-Yu Xie*

Department of Plant and Microbial Biology, North Carolina State University, Raleigh, NC, United States

We report to use the main protease (M\text{pro}) of SARS-Cov-2 to screen plant flavan-3-ols and proanthocyanidins. Twelve compounds, (–)-afzelechin (AF), (–)-epiafzelechin (EAF), (+)-catechin (CA), (–)-epicatechin (EC), (+)-gallocatechin (GC), (–)-epigallocatechin (EGC), (+)-catechin-3-O-gallate (CAG), (–)-epicatechin-3-O-gallate (ECG), (–)-gallocatechin-3-O-gallate (GCG), (–)-epigallocatechin-3-O-gallate (EGCG), procyanidin A2 (PA2), and procyanidin B2 (PB2), were selected for docking simulation. The resulting data predicted that all 12 metabolites could bind to M\text{pro}. The affinity scores of PA2 and PB2 were predicted to be −9.2, followed by ECG, GCG, EGCG, and CAG, −8.3 to −8.7, and then six flavan-3-ol aglycones, −7.0 to −7.7. Docking characterization predicted that these compounds bound to three or four subsites (S1, S1′, S2, and S4) in the binding pocket of M\text{pro} via different spatial ways and various formation of one to four hydrogen bonds. In vitro analysis with 10 available compounds showed that CAG, ECG, GCG, EGCG, and PB2 inhibited the M\text{pro} activity with an IC\text{50} value, 2.98 ± 0.21, 5.21 ± 0.5, 6.38 ± 0.5, 7.51 ± 0.21, and 75.3 ± 1.29 µM, respectively, while CA, EC, EGC, GC, and PA2 did not have inhibitory activities. To further substantiate the inhibitory activities, extracts prepared from green tea (GT), two muscadine grapes (MG), cacao, and dark chocolate (DC), which are rich in CAG, ECG, GCG, or/and PB2, were used for inhibitory assay. The resulting data showed that GT, two MG, cacao, and DC extracts inhibited the M\text{pro} activity with an IC\text{50} value, 2.84 ± 0.25, 29.54 ± 0.41, 29.93 ± 0.83, 153.3 ± 47.3, and 256.39 ± 66.3 µg/ml, respectively. These findings indicate that on the one hand, the structural features of flavan-3-ols are closely associated with the affinity scores; on the other hand, the galloylation and oligomeric types of flavan-3-ols are critical in creating the inhibitory activity against the M\text{pro} activity.

Keywords: flavan-3-ols, flavan-3-ol gallates, proanthocyanidins, COVID-19, green tea, muscadine grape, cacao, dark chocolate
INTRODUCTION

SARS-CoV-2 is a novel severe acute respiratory syndrome-related coronavirus strain and highly contagious to humans (Figure 1). Its infection on humans was reported in the early December of 2019 in Wuhan, China (Wang C. et al., 2020; Wu et al., 2020). On January 30, 2020, The World Health Organization (WHO) declared the outbreak of the coronavirus disease 2019 (COVID-19) emergency (World Health Organization, 2020a). On March 11, 2020, WHO announced the COVID-19 pandemic (World Health Organization, 2020b). As of October 22, 2020, it has infected ∼41,561,983 people and caused ∼1,135,289 deaths worldwide (data source from Johns Hopkins Coronavirus Resource Center). These numbers are continuously increasing every day. Extremely sadly, the humans do not know when this pandemic will end. Although hydroxychloroquine, chloroquine, and remdesivir were recommended for treating COVID-19 (Colson et al., 2020; Sehailia and Chemat, 2020; Wang M. et al., 2020), their therapeutic effects still remain for studies. For example, a new study showed that chloroquine could not treat COVID-19 (Hoffmann et al., 2020). Although 300 trials with different anti-virus medicines are being performed (Sanders et al., 2020), such as lopinavir and ritonavir (Cao et al., 2020), the fact is that no medicines show therapeutic effectiveness. Although in June 2020, dexamethasone, a steroid, was publically reported to decrease the death risk of COVID-19 patients (Khan and Htar, 2020; Selvaraj et al., 2020), more trials need to be performed to demonstrate its effectiveness. Furthermore, different proteins or genes of SARS-Cov-2, such as the main protease (Figure 1), have been targeted to screen medicines, however, no small molecules have been conclusively shown to be able to treat COVID-19 patients (Dai W. et al., 2020; Zhang et al., 2020). Currently, the humans are placing a hope on vaccines. However, no effective vaccines are ready for prevention. The potential risks of vaccines remain largely unknown. Making matters worse, more studies have shown that the originality and the transmission of this contagious virus are more complicated than the humans know. Studies have shown that in addition to aerosol transmission, this virus can be transmitted through gastrointestinal infection (Lamers et al., 2020; Xiao et al., 2020) and can stably stay for 3 h in air and 72 h on plastic and steal surfaces (van Doremalen et al., 2020). In addition to causing lung diseases, this virus has been found to cause other health complications, such as abdominal pain (Lamers et al., 2020) and neurologic abnormality (Helms et al., 2020). To the whole world surprise, one newest study revealed that SARS-Cov-2 existed in wastewater that had been stored in Barcelona, Spain since March 2019 (Chavarria-Miró et al., 2020), the time of which was 9 months earlier than the first report from Wuhan. This finding implies that SARS-Cov-2 might have been transmitted in humans before the outbreak. In summary, no medicines can treat COVID-19 and no vaccines can prevent this contagious disease. Therefore, effective treatments and preventions are urgently needed.

Flavan-3-ols and proanthocyanidins (PAs) are two groups of plant flavonoids (Figure 2; Xie and Dixon, 2005). They commonly exist in fruits, food products, and beverages, such as grape (Iacopini et al., 2008; Zhu et al., 2014; Yuzuak et al., 2018; Rousserie et al., 2019), strawberry (Lopez-Serrano and Barcelo, 1997; Fossen et al., 2004; Fischer et al., 2014), persimmon (Akagi et al., 2009), cranberry (Foo et al., 2000a,b), blueberry (Gu et al., 2002), cacao nuts (Murphy et al., 2003; Miller et al., 2009), chocolate (Schewe et al., 2002; Serafini et al., 2003),...
green tea (Liu et al., 2012; Zhao et al., 2017; Wang P. et al., 2020), and wines (Monagas et al., 2003). Common flavan-3-ol aglycones in these plant products include (−)-epicatechin (EC), (+)-catechin (CA), (−)-epigallocatechin (EGC), (+)-gallocatechin (GC), (−)-epiafzelechin (EAF), and (−)-afzelechin (AF) (Figure 2; Xie and Dixon, 2005). Common flavan-3-ol gallates include (−)-epicatechin-3-O-gallate (ECG), (+)-catechin-3-O-gallate (CAG), (−)-gallocatechin-3-O-gallate (GCG), (−)-epigallocatechin-3-O-gallate (EGCG), which are highly abundant in green tea (Dai X. et al., 2020; Wang P. et al., 2020). PAs are oligomeric or polymeric flavan-3-ols. In PAs, the lowest and upper units are termed as the starter and extension units, which are linked by interflavan bonds formed between the C₈ or C₆ of a lower unit and the C₄ of an upper unit (Figure 2). In addition, a second linkage is a C₂-O-C₇ ether bond between the starter unit and the extension unit. Based on the linkage numbers, PAs are classified into two types of structures, the dominant B-type characterized with an interflavan bond only and the uncommon A-type featured with an interflavan bond and an ether linkage (Xie and Dixon, 2005). Common dimeric B-types in fruits and beverages include procyanidin B1, B2, B3, and B4. Two examples of dimeric A-type PAs are procyanidin A1 and A2 (Xie and Dixon, 2005). Flavan-3-ols and PAs are potent antioxidants with multiple benefits to human health (Xie and Dixon, 2005). Multiple compounds from these two groups, such as CA, EPC, EGC, EGCG, procyanidin B2, and procyanidin A2 (Figure 2), have been shown to have antiviral function (de Bruyne et al., 1999; Iwasawa et al., 2009), antibacterial activity (Molan et al., 2001; Howell et al., 2005), anticancer (Ohata et al., 2005; Suganuma et al., 2011), anti-cardiovascular diseases (Loke et al., 2008; Panneerselvam et al., 2010; MacRae et al., 2019), and anti-aging diseases (Levites et al., 2003; Li et al., 2004; Weinreb et al., 2004). In particular, the anti-viral activity suggests that flavan-3-ols and
PAs are appropriate targets for screening potential anti-SARS-
Cov-2 medicines.

In this study, our goal was to use the M^{pro} of SARS-Cov-2 for
docking simulation to screen flavan-3-ols and PAs, to identify
potential active candidates, and to characterize their binding
similarity and difference among various structures. Then, based
on positive docking results, we used the M^{pro} of SARS-Cov-2 to
perform in vitro inhibitory experiments. Five compounds were
identified to have anti-M^{pro} activity. Crude extracts from green
tea, cacao, chocolate, and two muscadine grapes, which are rich
in flavan-3-ols and PAs, also showed inhibitory effects on the
M^{pro} activity.

MATERIALS AND METHODS

Candidates of Flavan-3-ols, Flavan-3-ol Gallates, and PAs for Docking Simulation

Main flavan-3-ol aglycones include (+)-epicatechin, (+)-
epiafzelechin, (+)-catechin (CA), (+)-epicatechin (EC), (+)-
gallocatechin (GC), and (+)-epigallocatechin (EGC). Galloylated
flavan-3-ol conjugates include (+)-epicatechin-3-O-gallate
(EGC), (–)-catechin-3-O-gallate, (–)-gallocatechin-3-O-gallate
(GCG), and (–)-epigallocatechin-3-gallate (EGCG). Dimeric PAs
include procyanidin A1, A2, B1, and B2. Fourteen structures are
listed in Figure 2. In addition, three known anti-viral medicines,
ebselen, cinanserin, and lopinavir, were used as positive controls.

Plant Materials

Five types of plant products rich in flavan-3-ols and dimeric
PAs were used for extraction. “Mao-fjian” tea is one type of top
green tea (Camellia sinensis) products in China. This product is
composed of newly leaves (0.8–1.2 cm in length) of early
spring sprouts (harvested around April 5 every year), which were
harvested in 2019. Ripen muscadine grape berries of FLH 13-11
spring sprouts (harvested around April 5 every year), which were
is composed of newly leaves (0.8–1.2 cm in length) of early

Extraction of Flavan-3-ols and PAs From
Green Tea, Cacao, Dark Chocolate, and
Muscadine Berry Powders

One gram of dry powder was suspended in 10 ml acetone:
deonized water (70:30) contained in a 50 ml falcon tube. The
tube was strongly vortexed for 5 min and then sonicated in a
water bath for 10 min at the room temperature, followed by
centrifugation at 4,000 rpm for 20 min. The resulting supernatant
was pipetted to a new 50 ml tube. The remained pellet was
extracted again with the same steps. Two extractions were pooled
together to obtain 20 ml in volume, which was reduced to 5.0 ml
by removing acetone with a nitrogen gas flow at the room
temperature. The tube containing the remained water phase was
added 1.0 ml chloroform and then strongly vortexed for 2.0 min,
followed by centrifugation at 4,000 rpm for 5 min. The resulting
lower chloroform phase containing non-polar compounds was
removed. This step was repeated once. The tube that contained
the remained water phase including flavan-3-ols and PAs was
added 5.0 ml ethyl acetate, strongly vortexed for 3.0 min, and then
centrifuged at 4,000 rpm for 5.0 min. The resulting upper ethyl
acetate phase containing flavan-3-ols and PAs was transferred to
a new 50 ml tube. This ethyl acetate extraction step was repeated
two times. The three times of ethyl acetate extractions were
pooled together and then dried completely with nitrogen flow
at the room temperature. The remained residue was dissolved in
DMSO to obtain 50 mg/ml extracts and stored in a −20°C freezer
until use.
**FIGURE 3** | The binding of flavan-3-ols and their gallates, proanthocyanidin B2 and A2, and three potential anti-SARS-Cov-2 drugs to the main protease (M⁰) shown by protein-ligand docking. (A) The 3D surface view of the SARS-Cov-2 M⁰ without and with the inhibitor peptide N3. The red rectangle frame shows the M⁰ substrate-binding pocket and the red amino acid residues show the N3 binding to the M⁰ substrate-binding pocket. (B–F) 10 compounds bind to the M⁰ substrate-binding pocket, (+)-atzelechin (AF) and (-)-epiafzelechin (EAF) (B), (+)-catechin (CA) and (-)-epicatechin (EPC) (C), (+)-gallocatechin (GC) and (-)-epigallocatechin (EGC) (D), (-)-gallocatechin gallate (GCG) and (-)-epigallocatechin gallate (EGCG) (E), and proanthocyanidin B2 and A2 (F). (G) Ebselen (EBS) and cinanserin (INN) bind to the M⁰ substrate-binding pocket. (H) Lopinavir (LOP) binds to M⁰ at a different position.

**In vitro Inhibition Assay of M⁰ Activity and Calculation of IC⁵₀ Values**

CA, EC, GC, EGC, CAG, GAG, ECG, EGCG, PA2, and PB2 were purchased from Sigma-Aldrich (St. Louis, MO) and dissolved in DMSO to prepare 1.0 mM stock solution. A 3CL Protease (M⁰) (SARS-CoV-2) Assay Kit (BPS bioscience, https://bpsbioscience.com/) was used to test the inhibitory activity of these 10 compounds. The steps of *in vitro* assay followed the
manufacturer’s protocol. In brief, each reaction was completed in a 25 µl volume in 96-well plates. Each reaction solution contains 150 ng recombinant M\textsuperscript{PrO} (the final concentration in the reaction, 6 ng/µl), 1.0 mM DDT, 50 µΜ fluorogenic substrate, and CA, EPC, GC, EGC, CAG, GAG, ECG, EGCG, PA2, PB2 (final concentrations, 0, 0.1, 0.5, 1, 5, 10, 50, 100, 150, and 200 µΜ) or one plant extract (final concentrations, 0, 1, 10, 100, 1,000 µg/ml) in pH 8.0 50 mM Tris-HCl and 5.0 mM EDTA buffer. GC376 (50 µΜ) was used as positive control and Tris-HCl-EDTA buffer was used as negative control. The reaction mixtures were incubated for 4.0 h at the room temperature. The fluorescence intensity of each reaction was measured and recorded on a microtiter plate-reading fluorimeter (BioTek's Synergy H4 Plate Reader for detect fluorescent and luminescent signals). The excitation wavelength was 360 nm and the detection emission wavelength was 460 nm. Each concentration of compounds and extracts was tested five times. A mean value was calculated using five replicates. One-way analysis of variance (ANOVA) was performed to evaluate the statistical significance. The $P$-value < 0.05 means significant differences.

After fluorescence values were recorded, based on negative control, the fluorescent intensities of each reaction were converted to percentages, which were used to develop inhibitory effect curves with the Originlab software (https://www.originlab.com/). All data were imported to the Originlab workbook, which had an Analysis Toolbar including a Rank model fitting tool (a non-linear fitting tool). After data were fitted with the non-linear fitting tool, a Dose-Response Curve (DoseRes) function was used to develop non-linear regression curves. The outputs of the non-linear regression included inhibitory effect curves, standard errors, the half maximal inhibitory concentration (IC\textsubscript{50}) values and a 95% confidence interval (CI), and a range of values including IC5 with a 95% CI.

### Evaluation of Docking Simulation With Receiver Operating Characteristic Curve

Based on actual positive and negative inhibition data obtained from in vitro assay, we used receiver operating characteristic (ROC) curve to evaluate the performance confidence of the docking simulation. To develop a ROC curve, we used “1” to stand for positives and “0” to stand for negatives. Accordingly, the sensitivity and 1-specificity false positive values were calculated for each docking score (Supplementary Table 1), and then applied to the OriginLab software to create a ROC plot. Based on the obtained ROC plot, a potential cut off value for affinity score was obtained.

### RESULTS

#### Docking Simulation of Compounds Binding to M\textsuperscript{PrO}

Theoretical compound screening for inhibitors of the SARS-CoV-2 M\textsuperscript{PrO} is an effective approach to identify potential candidates that can be used for trials to test their inhibitory activity against SARS-CoV-2 (Xue et al., 2008; Pillaiyar et al., 2016; Dai W. et al., 2020; Jin et al., 2020b; Zhang et al., 2020). To predict whether flavan-3-ol aglycones, their gallates, and dimeric PAs (Figure 2) could inhibit the M\textsuperscript{PrO} activity, we performed docking simulation via two types of publicly available software, Dock Prep tool of UCSF-Chimera and AutoDock vina. The resulting docking data showed that all flavan-3-ol aglycones, flavan-3-ol gallates, and dimeric procyanidins tested (PA2 and PB2) (Figure 2) could bind to the same location of M\textsuperscript{PrO}, which is the substrate binding pocket bound by the N3 inhibitor (Figures 3A–F). Given that the docking simulation was completed from any positions, different poses of binding were clustered (Supplementary Figure 1) to determine the optimal position for each ligand (Figures 3A–F). In addition, two antiviral control compounds, ebselen and cinanserin, bound to the same binding pocket (Figure 3G). In contrast, the antiviral lopinavir bound to a different location (Figure 3H).

Based on the optimal pose of ligand (Figures 3B–F), the affinity scores were recorded from the docking simulation. The resulting best affinity scores were $-7.0$ to $-7.7$ for six flavan-3-ol aglycones, $-8.3$ to $-8.7$ for four flavan-3-ol gallates, and $-9.2$ for two dimeric proanthocyanidins (Table 1). All these scores were lower than those of ebselen and cinanserin, $-6.6$ and $-5.4$. The affinity scores of the dimeric PAs and flavan-3-ol-gallates were lower than $-8.0$ for lopinavir. These data suggested that flavan-3-ols, flavan-3-ol gallates, and dimeric PAs were appropriate candidates with potentially inhibitory effects on the M\textsuperscript{PrO} activity. During our manuscript revision, a recent in silico docking for flavan-3-ols in green tea reported similar affinity score ranging from $-7.2$ to $9.0$ (Ghosh et al., 2020). Another in silico docking reported the procyanidin B\textsubscript{7} and A2 affinity scores, $-8.0$ and $-8.2$ (Prasanth et al., 2020). These two studies together with ours suggest that different types of software can give similar simulation data. In addition, potential binding to other sites such as surface was observed in the docking simulation. However, compared with those promising affinity scores (Table 1) obtained from the

| Molecules                          | Affinity score (kcal/mol) | Molecular weight (g/mol) |
|-----------------------------------|---------------------------|--------------------------|
| Procyanidin B2 (PB2)              | $-9.2$                    | 578.55                   |
| Procyanidin A2 (PA2)              | $-9.2$                    | 576.5                    |
| (-)-epigallocatechin-3-O-gallate  | $-8.7$                    | 458.37                   |
| (-)-gallocatechin-3-O-gallate     | $-8.7$                    | 458.37                   |
| (-)-epicatechin-3-O-gallate       | $-8.7$                    | 442.37                   |
| (-)-catechin-3-O-gallate          | $-8.3$                    | 442.37                   |
| (-)-epigallocatechin              | $-7.7$                    | 306.27                   |
| (-)-epicatechin                   | $-7.6$                    | 306.27                   |
| (-)-gallocatechin                 | $-7.5$                    | 290.27                   |
| (-)-catechin                      | $-7.5$                    | 290.27                   |
| (-)-epiafzelechin (EAF)           | $-7.5$                    | 274.26                   |
| (-)-afzelechin (AF)               | $-7.0$                    | 274.26                   |
| Lopinavir (LOP)                   | $-8.0$                    | 628.81                   |
| Ebselen (EBS)                     | $-6.6$                    | 274.17                   |
| Cinanserin (CIN)                  | $-5.4$                    | 340.49                   |
substrate binding site, the affinity scores from other sites were bigger than $-2.0$, which were insignificant for further analysis.

**Spatial Binding Characteristics at Different Subsites of M\textsubscript{Pro}**
The substrate binding pocket of M\textsubscript{Pro} has four subsites, S1', S1, S2, and S4 (Dai W. et al., 2020). Substrate-binding analysis was completed for ebselen (positive control) and 14 compounds (Figure 2). The results predicted different binding features among ebselen, six flavan-3-ol aglycones, four flavan-3-ol-gallates, and two dimeric PAs. The two benzene rings of ebselen were predicted to face to S1 and S1' (Figure 4A), while the 14 compounds were predicted to face to three or four subsites (Figures 4B–E). The A-ring and B-ring of EGC were predicted to face to S2/S4 and S1, respectively (Figure 4B). The same patterns were predicted for AF, EAF, CA, EPC, and GC. The A-ring, B-ring, and the gallate ester group of EGCG were predicted to face to S2, S1', and S1, respectively (Figure 4C). The same patterns were obtained for CAG, ECG, and GCG. In the PA1 and PA2 binding, the A-ring and B-ring of the starter unit and the B-ring of the upper unit were predicted to face to S1, S4, and S1', respectively (Figure 4D). In PB1 and B2 docking modeling, the B-ring of the starter unit and the A-ring and B-ring of upper unit were predicted to face to S1', S1, and S2, respectively (Figure 4E).

**FIGURE 4** | Features of ebselen, (--)-epigallocatechin, (--)-epigallocatechin 3-O-gallate (EGCG), procyanidin A2 (PA2), and procyanidin B2 (PB2) binding to subsites in M\textsubscript{Pro} predicted by protein-ligand docking modeling. (A) Ebselen binds to S1 and S1' subsites. (B) (--)-epigallocatechin binds to S1, S2/S4 subsites of the M\textsubscript{Pro}. (C) (--)-epigallocatechin 3-O-gallate binds to the S1, S1', and S2 subsites of M\textsubscript{Pro}. (D) procyanidin A2 binds to the S1', S1, and S4 subsites of M\textsubscript{Pro}. (E) Procyanidin B2 binds to the S1, S1', and S2 subsites of M\textsubscript{Pro}.
Potential Hydrogen Bonds Formed Between Compounds and the Binding Pocket of M<sub>pro</sub>

This docking simulation predicted that the binding of these compounds to the substrate binding pocket was via the formation of hydrogen bonds. Based on the best affinity score of each compound (Table 1), the docking simulation could predict the most potential hydrogen bonds formed between each compound and the binding pocket of M<sup>pro</sup>. The resulting data showed different features of the hydrogen bond number and potential linkage positions between compounds and amino acids of M<sup>pro</sup> (Figures 5A–J). Three hydrogen bonds were predicted to be formed between AF, EAF, CA, or EC and M<sup>pro</sup> (Figures 5A–D). The linkages of those three hydrogen bonds were formed between

![Diagram of hydrogen bonding](image)

**FIGURE 5 |** Potential hydrogen bonds formed between M<sub>pro</sub> and 10 compounds predicted by ligand-protein modeling. These bond positions and numbers formed between 10 various metabolites and the binding pocket of M<sub>pro</sub> were predicted based on the best affinity scores of each compound (Table 1). (+)-Afzelechin (AF) (A), (-)-Epiafzelechin (B), (+)-Catechin (CA) (C), and (-)-Epicatechin (D) were predicted form three hydrogen bonds with M<sub>pro</sub>. The hydrogen patterns were the same between AF and CA, while those were the same between EAF and EC. (+)-Gallocatechin (E), (-)-Epigallocatechin (F), and (-)-Gallocatechin gallate (G) were predicted to form one hydrogen with M<sub>pro</sub>. (-)-Epigallocatechin gallate was predicted to form three hydrogen bonds with M<sub>pro</sub>. Procyanidin A2 (I) and B2 (J) were predicted to form one and three hydrogen bonds with M<sub>pro</sub>.
AF and M\textsuperscript{pro} via O\textsubscript{1}-Glu\textsubscript{166}, C\textsubscript{3}-O-Glu\textsubscript{166}, and C\textsubscript{7}-O-Leu\textsubscript{141} (Figure 5A), between EAF and M\textsuperscript{pro} via O\textsubscript{1}-Glu\textsubscript{166}, C\textsubscript{7}-O-Leu\textsubscript{141}, and C\textsubscript{4'}-O-Gln\textsubscript{189} (Figure 5B), between CA and M\textsuperscript{pro} via O\textsubscript{1}-Glu\textsubscript{166}, C\textsubscript{3}-O-Glu\textsubscript{166}, and C\textsubscript{4'}-O-Leu\textsubscript{141} (Figure 5C), and between EC and M\textsuperscript{pro} via O\textsubscript{1}-Glu\textsubscript{166}, C\textsubscript{7}-O-Thr\textsubscript{190}, and C\textsubscript{4'}-O-Gln\textsubscript{189} (Figure 5D). GC, EGC, and GCG were predicted to form one hydrogen bond with M\textsuperscript{pro} via O\textsubscript{1}-Glu\textsubscript{166} (Figures 5E–G). EGC and M\textsuperscript{pro} were predicted to form four hydrogen bonds via O\textsubscript{1}-Glu\textsubscript{166}, C\textsubscript{7}-O-Thr\textsubscript{190}, C\textsubscript{5}-O-Phe\textsubscript{140}, and galate-3-O-Gly\textsubscript{143} (Figure 5H). PA2 and M\textsuperscript{pro} were predicted to form one hydrogen bond via C\textsubscript{3}-O-Gly\textsubscript{143}. PB2 and M\textsuperscript{pro} were predicted to form three hydrogen bonds via C\textsubscript{5}-O-Gly\textsubscript{143} and C\textsubscript{5}-O-Cys\textsubscript{145} on the

![FIGURE 6](image-url) | Inhibitory effects of four flavan-3-ol-gallates, four flavan-3-ol aglycones, procyanidin A2 (PA2), and procyanidin B2 (PB2) on the M\textsuperscript{pro} activity of SARS-CoV-2. Inhibitory curves show that (+)-catechin-3-O-gallate (CAG) (A), (+)-epicatechin-3-O-gallate (ECG) (B), (+)-gallocatechin-3-O-gallate (GCG) (C), (+)-epigallocatechin-3-O-gallate (EGCG) (D), and PB2 (E) inhibit the activity of M\textsuperscript{pro} with an IC\textsubscript{50} 2.98 ± 0.21 µM, IC\textsubscript{50} 5.21 ± 0.52 µM, IC\textsubscript{50} 6.38 ± 0.52 µM, IC\textsubscript{50} 7.51 ± 0.21 µM, and IC\textsubscript{50} 7.51 ± 0.92 µM, respectively. (F) Inhibitory effects of 100 µM (+)-epicatechin (EC), (+)-catechin (CA), EGC, CAG, ECG, GCG, EGCG, PA2, and PB2 on the activity of M\textsuperscript{pro}. Compared with the negative control, the activity of M\textsuperscript{pro} is inhibited by 40, 40, 44.4, 50, 81.5, and 100% by 100 µM CAG, ECG, EGCG, GCG, PB2, and positive control GC376. 95% CI: 95% confidence interval and (value 1, value 2): values in the range with 95% CI.
B ring of the upper unit and C$_3$-O-Glu$_{166}$ on the C-ring of the starter unit. Furthermore, all hydrogen-binding distances were different from 1.833Å between PA2 and M$^{pro}$ (Figure 5I) to 2.541Å between EGC and M$^{pro}$ (Figure 5F).

**In vitro Inhibitory Effects of 10 Compounds on the M$^{pro}$ Activity**

To understand the effects of these docking promising compounds on the M$^{pro}$ activity, we used CA, EPC, GC, EGC, CAG, ECG, GCG, EGCG, PA2, and PB2 to perform *in vitro* inhibition assay. The resulting inhibitory curves showed that CAG, ECG, GCG, EGCG, and PB2 inhibited the M$^{pro}$ activity (Figure 6). The values of the half maximal inhibitory concentration (IC$_{50}$) for CAG, ECG, GCG, EGCG, and PB2 were $\sim$2.98 ± 0.21, 5.21 ± 0.5, 6.38 ± 0.5, 7.51 ± 0.21, and 75.3 ± 1.29 µM, respectively (Figures 6A–E). The resulting data showed when the concentrations of these compounds were increased, such as 100 µM, the inhibition of PB2 was more effective than that of CAG, GCG, and EGCG (Figure 6F). In contrast, the *in vitro* analysis did not detect that CA, EPC, GC, EGC, and PA2 in a range of concentrations from 0 to 500 µM tested could inhibit the M$^{pro}$ activity (Figure 6F and Supplementary Figures 2A–E).

**Evaluation With Receiver Operating Characteristic Curve**

Based on *in vitro* assay, a receiver operating characteristic (ROC) curve was established to evaluate the performance confidence of the docking simulation. *In vitro* inhibition data and affinity scores were used to calculate sensitivity and 1-specificity positive values (Supplementary Table 1), which were used to establish a ROC curve. The resulting plot showed that the area under the ROC (AUROC) was 0.8864 (Supplementary Figure 3), indicating an excellent performance of the docking simulation. The resulting data indicated that the docking scores higher than −7.6 could be used to predict the non-inhibition of flavan-3-ol aglycones against the M$^{pro}$ activity. On other hand, except for PA2, the docking scores lower than −8.3 could be used to predict the inhibition of flavan-3-ol conjugates and dimers against the M$^{pro}$ activity. Accordingly, this ROC evaluation indicated that the docking simulation was appropriate in predicting the inhibitory activity of flavan-3-ols and their conjugates and dimers.

**In vitro Inhibitory Effects of Plant Extracts on the M$^{pro}$ Activity**

Green tea (Zhao et al., 2017; Wang P. et al., 2020), two muscadine grape cultivar berries (including seeds and skin)
(Yuzuak et al., 2018), and dark chocolate and cacao (Takahashi et al., 1999; Schewe et al., 2001) are rich in flavan-3-ol gallates and dimeric PAs. To understand whether these plant products could inhibit the \( \text{M}^{\text{pro}} \) activity of SARS-CoV-2, we extracted flavan-3-ol gallates and dimeric PAs from the five types of materials and then completed in vitro assays. The resulting data showed that all extracts of these products could inhibit the \( \text{M}^{\text{pro}} \) activity (Figures 7A–F). The green tea extracts showed the highest inhibitory activity with an IC\(_{50}\) 2.84 ± 0.25 \( \mu \)g/ml. At 10 \( \mu \)g/ml, the green tea extract tea completely inhibited the \( \text{M}^{\text{pro}} \) activity (Figure 7A). In recent, we reported that green tea extracts contained a high content of EGCG, a relatively high content of ECG, and appropriate contents of dimeric procyanidin B1, B2, B3, and B4 (Zhao et al., 2017; Dai X. et al., 2020; Wang P. et al., 2020). Thus, the inhibitory activity of green tea extracts resulted from these compounds. The extracts of two muscadine grapes FLH 13-11 and FLH17-66 inhibited the \( \text{M}^{\text{pro}} \) activity with an IC\(_{50}\) 29.54 ± 0.41 \( \mu \)g/ml and an IC\(_{50}\) 29.93 ± 0.83 \( \mu \)g/ml. At 100 \( \mu \)g/ml, the extracts of two muscadine grapes completely inhibited the \( \text{M}^{\text{pro}} \) activity (Figures 7B–F). In recent, we also reported that these extracts of two muscadine cultivar berries contained ECGG, ECG, and procyanidin B1-B3 and B5-B8 (Yuzuak et al., 2018). The inhibitory activity of the muscadine extracts was associated with the presence of these compounds. Cacao and dark chocolate extracts were shown to inhibit the \( \text{M}^{\text{pro}} \) activity when the extract concentrations tested were higher than 10 \( \mu \)g/ml and their IC\(_{50}\) values were 153.3 ± 47.3 \( \mu \)g/ml and 256.39 ± 66.3 \( \mu \)g/ml, respectively (Figures 7D,E). Given that ECG, EGCCG, and PB2 were characterized to be main plant flavonoids in the cacao and dark chocolate extracts (Takahashi et al., 1999; Schewe et al., 2001), the inhibitory activity of these two extracts resulted from these compounds. We further compared the inhibitory activity of all extracts at 100 \( \mu \)g/ml tested, the results showed that the extracts of green tea and two muscadine grapes completely inhibited the \( \text{M}^{\text{pro}} \) activity and the extracts of cacao and dark chocolate reduced the \( \text{M}^{\text{pro}} \) activity by 40–50% (Figure 7F).

**DISCUSSION**

Both docking simulation and in vitro assays showed that the stereo configurations, galloylation, and oligomeric types of flavan-3-ols affected the ligand-protein binding features and inhibitory activity. Flavan-3-ols and PAs are two groups of plant flavonoids (Xie and Dixon, 2005). PAs are oligomeric or polymeric flavan-3-ols. Flavan-3-ol aglycones have four different stereo configurations at C\(_2\) and C\(_3\) on the C-ring (Figure 2). For example, (+)-catechin at C\(_2\) and C\(_3\) has a 2R, 3S-2, 3-trans configuration (Figure 2). Its isomer (−)-epicatechin has a 2R, 3R-2, 3-cis configuration. (−)-Catechin and (±)-epicatechin have a 2S, 3R-2, 3-trans and a 2S, 3S-2, 3-cis configuration, respectively (Xie and Dixon, 2005). In addition, the number of hydroxyl groups on the B-ring, such as one on AF, two on CA, and three on GA (Figure 2), diversifies structures. To understand whether these stereo configurations and the hydroxyl group numbers can affect docking simulation and be associated with inhibitory activity, we screened and tested representative flavan-3-ol aglycones, flavan-3-ol gallates, and dimeric PAs. Six flavan-3-ol aglycones included AF, EAF, CA, EC, GC, and EGC (Figure 2), which represented three types of hydroxyl group numbers on the B-ring and two types of stereo configurations at C\(_2\) and C\(_3\). All six compounds were predicted to be able to bind to the binding pocket of \( \text{M}^{\text{pro}} \) (Figure 3). It was interesting that the affinity scores decreased as the number of hydroxyl groups on the B-ring of flavan-3-ols increased (Table 1). This datum indicates that more hydroxyl groups on the B-ring increase the binding capacity to \( \text{M}^{\text{pro}} \). Furthermore, the docking simulation showed that the galloylation at C\(_3\)-OH of CA, EC, GC, and EGC and dimerization of EC decreased the affinity scores (Table 1), indicating that the galloylation and oligomerization could increase the binding capacity to \( \text{M}^{\text{pro}} \). Meanwhile, the galloylation of flavan-3-ols increases the acidity of flavan-3-ols and their molecular weights (Table 1). These chemical feature changes might also be associated with the increased binding capacity. Based on the docking simulation and affinity scores, we hypothesized that 12 compounds (Figure 2) could have an inhibitory activity against the \( \text{M}^{\text{pro}} \) activity. However, in vitro assays only detected the positively inhibitory effects of galloylated flavan-3-ols, including CAG, ECG, GCG, and EGCCG, on the \( \text{M}^{\text{pro}} \) activity (Figure 6). No inhibitory activity was detected in the assays of CA, EC, GC, and EGC (Supplementary Figure 2), although their affinity scores were from −7.5 to −7.7. These data indicate that although positive docking data are useful to screen candidates, in vitro test experiments are necessary to show an activity. Furthermore, these data showed that the galloylation of these flavan-3-ols created the inhibitory activity against \( \text{M}^{\text{pro}} \). In addition, it was interesting that although the affinity scores of PA2 and PB2 were the same, −9.2, PB2 but not PA2 showed an inhibitory activity against \( \text{M}^{\text{pro}} \) (Figure 6E and Supplementary Figure 2). This datum indicates that the dimeric PA types are closely associated with the inhibitory activities. Based on these in vitro assay data and affinity scores, a ROC curve was developed to evaluate the performance confidence of docking simulations for screening flavan-3-ols and PAs (Supplementary Figure 3 and Supplementary Table 1). Although only 12 compounds were screened with docking simulation and 10 compounds were tested in vitro, the resulting ROC curve could provide a promising prediction. Based on the ROC curve, the affinity score −8.3 could be proposed to be a cut off value to screen flavan-3-ol derivatives for anti-SARS-CoV-2 candidates.

Although it was difficult to test more flavan-3-ol gallates and dimeric PAs due to the unavailability of compounds, we could take advantage of natural sources to understand the inhibitory effects of more flavan-3-ol gallates and dimeric PAs on the \( \text{M}^{\text{pro}} \) activity. Our previous UPLC-MS based profiling showed that green tea (GT) produced not only EGCG and PB2 but also ECG, GCG, CAG, procyanidin B1 (PB1), PB3, and PB4 (Zhao et al., 2017; Dai X. et al., 2020; Wang P. et al., 2020). We prepared extracts from GT and tested their activity. The resulting inhibitory activity was effective and the concentration at 10 \( \mu \)g/ml could completely inhibit the \( \text{M}^{\text{pro}} \) activity (Figure 7A). These data suggest that in addition to ECG, GCG, CAG, EGCCG, and PB2 tested, PB1, PB3, and PB4 may provide additive
inhibitory activity against the M\textsuperscript{pro} activity. In addition, our recent HPLC-MS/MS based profiling reported that the berries (including seeds and peels) of two muscadine grape cultivars, FLH 13-11 FL and FLH 17-66 FL, produced four flavan-3-ol aglycones, 18 galloylated or glycosylated conjugates, and eight dimeric procyanidins (Yuzuk et al., 2018). The extracts of these two muscadine grapes showed an effective inhibitory activity against the M\textsuperscript{pro} activity (Figures 7B,C), indicating that those untested dimeric PAs and flavan-3-ol conjugates might enhance the inhibitory activity. We recently analyzed cacao nut and DW extracts and identified PB1 and PB2 in the extracts. These two extracts also showed appropriately inhibitory activity against the M\textsuperscript{pro} activity. Based on these flavan-3-ol, flavan-3-ol gallate, and dimeric PA-containing natural resources, we hypothesize that those flavan-3-ol gallates, dimeric PAs, and oligomeric PAs untested have inhibitory effects on the M\textsuperscript{pro} activity. Besides, we anticipate that it is valuable to continuously screen more flavan-3-ol gallates and other derivatives as well as PAs, from which effective compounds can be identified for anti-SARS-Cov-2 efforts. In summary, although these natural extracts have not been tested for the inhibitory efficacy in animals and humans, based on their inhibitory activity in vitro, we propose that an increased consumption of these common products can enhance preventing against SARS-Cov-2 and improving the COVID-19.

Conclusion, both docking simulation and in vitro assay showed that (−)-catechin-3-O-gallate (7), (−)-epicatechin-3-O-gallate (8), (−)-gallocatechin-3-O-gallate (9), and (−)-epigallocatechin-3-O-gallate (10), procyanidin B1 (11) and B2 (12) inhibited the M\textsuperscript{pro} activity of SARS-CoV-2. Moreover, these compound-rich extracts of green tea, muscadine grape, cacao, and dark chocolate also inhibited the M\textsuperscript{pro} activity. Given that there is not an effective medicine for the treatment of COVID-19 and not a vaccine for preventing against the SARS-CoV-2 infection and transmission, these data recommend that these nutraceutical compounds and extracts of green tea, grape, and cacao can be utilized to interfere the devastation of SARS-CoV-2.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

AUTHOR CONTRIBUTIONS

D-YX perceived and supervised the entire project, prepared figures, drafted, and finalized the manuscript. YZ completed docking analysis, completed experiments, prepared figures, and drafted materials, methods, and results. Both authors contributed to the article and approved the submitted version.

ACKNOWLEDGMENTS

We are grateful to our Borlaug Fellow, Dr. Maria Elena Cazar from Universidad de Cuenca, Ecuador, for kindly providing us cacao powder and dark chocolate.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpls.2020.601316/full#supplementary-material

REFERENCES

Akagi, T., Ikegami, A., Suzuki, Y., Yoshida, J., Yamada, M., Sato, A., et al. (2009). Expression balances of structural genes in shikimate and flavonoid biosynthesis cause a difference in proanthocyanidin accumulation in persimmon ( Diospyros kaki Thunb.) fruit. Planta 230, 899–915. doi: 10.1007/s00425-009-0911-6

Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., et al. (2020). A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N. Engl. J. Med. 382, 1787–1799. doi: 10.1056/NEJMc2008043

Chavarria-Miró, G., Anfruns-Estrada, E., Guix, S., Paraira, M., Galofrè B., Sánchez, G., et al. (2020). Sentinel surveillance of SARS-CoV-2 in wastewater anticipates the occurrence of COVID-19 cases. medRxiv. [Preprint]. doi: 10.1101/2020.06.13.20129627

Chen, L., Gui, C., Luo, X., Yang, Q., Günther, S., Scandella, E., et al. (2005). Cinanserin is an inhibitor of the 3C-like protease of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro. J. Virol. 79, 7095–7103. doi: 10.1128/JVI.79.11.7095-7103.2005

Colson, P., Rolain, J.-M., and Raoult, D. (2020). Chloroquine for the 2019 novel coronavirus SARS-CoV-2. Int. J. Antimicrob. Agents 55, 105923–105923. doi: 10.1016/j.ijantimicag.2020.105923

Dai, W., Zhang, B., Jiang, X.-M., Su, H., Li, J., Zhao, Y., et al. (2020). Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science 368, 1331–1335. doi: 10.1126/science.abb4489

Dai, X., Liu, Y., Zhiang, J., Yao, S., Liu, L., Jiang, X., et al. (2020). Discovery and characterization of tannase genes in plants: roles in hydrolysis of tannins. New Phytol. 226, 1104–1116. doi: 10.1111/nph.16425

de Bruyne, T., Pieters, L., Witvrouw, M., de Clercq, E., vanden Berghe, D., and Vlieg, A. J. (1999). Biological evaluation of proanthocyanidin dimers and related polyphenols. J. Nat. Prod. 62, 954–958. doi: 10.1021/jn9804810

Fischer, T. C., Mirbath, B., Rentsch, J., Sutter, C., Ring, L., Flachowsky, H., et al. (2014). Premature and ectopic anthocyanin formation by silencing of anthocyanidin reductase in strawberry ( Fragaria x ananassa). New Phytol. 201, 440–451. doi: 10.1111/nph.12528

Foo, L. Y., Lu, Y., Howell, A. B., and Vorsa, N. (2000a). The structure of cranberry proanthocyanidins which inhibit adherence of uropathogenic P-fimbriated Escherichia coli in vitro. Phytochemistry 54, 173–181. doi: 10.1016/S0031-9422(99)00573-7

Foo, L. Y., Lu, Y., Howell, A. B., and Vorsa, N. (2000b). A-type proanthocyanidin trimers from cranberry that inhibit adherence of uropathogenic P-fimbriated Escherichia coli. J. Nat. Prod. 63, 1225–1228. doi: 10.1021/jn980128u

Fossen, T., Rayyan, S., and Andersen, O. M. (2004). Dimeric anthocyanins from strawberry ( Fragaria ananassa) consisting of pelargonidin 3-glucoside covalently linked to four flavan-3-ols. Phytochemistry 65, 1421–1428. doi: 10.1016/j.phytochem.2004.05.003

Ghosh, R., Chakraborty, A., Biswas, A., and Chowdhuri, S. (2020). Evaluation of green tea polyphenols as novel corona virus (SARS CoV-2) main protease (Mpro) inhibitors - an in silico docking and molecular dynamics simulation study. J. Biomol. Struct. Dyn. 1–13. doi: 10.1080/07391102.2020.17 93818

Gu, L., Kelm, M., Hammerstone, J. F., Beecher, G., Cunningham, D., AV Annozzi, S., et al. (2002). Fractionation of polymeric procyanidins from lowbush blueberry and quantification of procyanidins in selected foods with an
World Health Organization (2020b). WHO Director-General’s Opening Remarks at the Media Briefing on COVID-19 - 11 March 2020. World Health Organization Geneva: Switzerland.  
Wu, Y.-C., Chen, C.-S., and Chan, Y.-J. (2020). The outbreak of COVID-19: an overview. J. Chin. Med. Assoc. 83, 217–220. doi: 10.1097/JCMA.0000000000000270  
Xiao, F., Tang, M., Zheng, X., Liu, Y., Li, X., and Shan, H. (2020). Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology 158, 1831.e3–1833.e3. doi: 10.1053/j.gastro.2020.02.055  
Xie, D.-Y., and Dixon, R. A. (2005). Proanthocyanidin biosynthesis - still more questions than answers? Phytochemistry 66, 2127–2144. doi: 10.1016/j.phytochem.2005.01.008  
Xue, X., Yu, H., Yang, H., Xue, F., Wu, Z., Shen, W., et al. (2008). Structures of two coronavirus main proteases: Implications for substrate binding and antiviral drug design. J. Virol. 82, 2515–2527. doi: 10.1128/JVI.02114-07  
Yuzuak, S., Ballington, J., and Xie, D. Y. (2018). HPLC-qTOE-MS/MS-based profiling of flavan-3-ols and dimeric proanthocyanidins in berries of two muscadine grape hybrids FLH 13-11 and FLH 17-66. Metabolites 8:57. doi: 10.3390/metabo8040057  
Zhang, L., Lin, D., Sun, X., Curth, U., Drosten, C., Sauerhering, L., et al. (2020). Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science 368, 409–412. doi: 10.1126/science.abb3405  
Zhao, L., Jiang, X. L., Qian, Y. M., Wang, P. Q., Xie, D. Y., Gao, L. P., et al. (2017). Metabolic characterization of the anthocyanidin reductase pathway involved in the biosynthesis of Flavan-3-ols in elite Shuchazao Tea (Camellia sinensis) cultivar in the field. Molecules 22:21. doi: 10.3390/molecules22122241  
Zhu, Y., Peng, Q. Z., Li, K. G., and Xie, D. Y. (2014). Molecular cloning and functional characterization of the anthocyanidin reductase gene from Vitis bellula. Planta 240, 381–398. doi: 10.1007/s00425-014-2094-2  

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Zhu and Xie. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.